We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+20.89%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$6.13B
AUM Growth
+$563M
Cap. Flow
-$172M
Cap. Flow %
-2.8%
Top 10 Hldgs %
24.72%
Holding
175
New
20
Increased
65
Reduced
40
Closed
23

Top Buys

Rank Stock Value
1
CLDX icon
Celldex Therapeutics
CLDX
+$59.7M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$54.7M
3
LXEO icon
Lexeo Therapeutics
LXEO
+$37.3M
4
MNDY icon
monday.com
MNDY
+$32.9M
5
XMTR icon
Xometry
XMTR
+$28.5M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$79.8M
2
EXAS
Exact Sciences
EXAS
+$51.4M
3
SHLS icon
Shoals Technologies Group
SHLS
+$42.6M
4
ASND icon
Ascendis Pharma A/S
ASND
+$39.3M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$39.2M

Sector Composition

Rank Sector Weight
1 Healthcare 39.38%
2 Technology 24.68%
3 Industrials 16.87%
4 Consumer Discretionary 8.76%
5 Communication Services 2.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MASS icon
101
908 Devices
MASS
$313M
$16.1M 0.26%
1,430,995
– –
VCYT icon
102
Veracyte
VCYT
$4.77B
$15.5M 0.25%
564,000
-168,000
-23% -$4.06M
BRKR icon
103
Bruker
BRKR
$9.79B
$15.5M 0.25%
210,365
– –
RPRX icon
104
Royalty Pharma
RPRX
$26.2B
$15M 0.24%
533,975
-470,171
-47% -$12.9M
RCKT icon
105
Rocket Pharmaceuticals
RCKT
$351M
$14.7M 0.24%
490,732
-407,268
-45% -$8.99M
RCM
106
DELISTED
R1 RCM Inc. Common Stock
RCM
$14.5M 0.24%
1,375,980
+640,275
+87% +$7.26M
VKTX icon
107
Viking Therapeutics
VKTX
$3.84B
$14M 0.23%
750,000
– –
INZY
108
DELISTED
Inozyme Pharma
INZY
$13.5M 0.22%
3,179,837
+54,837
+2% +$195K
GXO icon
109
GXO Logistics
GXO
$5.8B
$13.5M 0.22%
220,170
-5
-0% -$280
COGT icon
110
Cogent Biosciences
COGT
$7.07B
$13.1M 0.21%
2,232,968
+82,968
+4% +$636K
ROIV icon
111
Roivant Sciences
ROIV
$24.8B
$12.8M 0.21%
1,143,938
-546,362
-32% -$5.32M
APLS
112
DELISTED
Apellis Pharmaceuticals
APLS
$12.6M 0.21%
+209,794
New +$10.6M
IDYA icon
113
IDEAYA Biosciences
IDYA
$3.5B
$11.9M 0.19%
335,000
– –
IEX icon
114
IDEX
IEX
$17.3B
$11.9M 0.19%
54,643
-3,649
-6% -$736K
SO icon
115
Southern Company
SO
$106B
$11.9M 0.19%
+169,005
New +$11.6M
NTLA icon
116
Intellia Therapeutics
NTLA
$1.55B
$11.4M 0.19%
372,665
– –
VST icon
117
Vistra
VST
$50.1B
$11.3M 0.18%
292,907
+179,769
+159% +$6.25M
VRSK icon
118
Verisk Analytics
VRSK
$26.1B
$11.1M 0.18%
46,555
+8,674
+23% +$2.05M
RVMD icon
119
Revolution Medicines
RVMD
$40.9B
$10.4M 0.17%
361,000
– –
EHC icon
120
Encompass Health
EHC
$11B
$10.1M 0.17%
151,644
-18,464
-11% -$1.2M
ARWR icon
121
Arrowhead Research
ARWR
$12.3B
$9.59M 0.16%
+313,289
New +$8.32M
ANAB icon
122
AnaptysBio
ANAB
$1.63B
$9.15M 0.15%
427,000
– –
SYY icon
123
Sysco
SYY
$40.6B
$8.79M 0.14%
120,249
-14,710
-11% -$1.02M
GPI icon
124
Group 1 Automotive
GPI
$3.53B
$8.67M 0.14%
28,438
+11,207
+65% +$3.05M
SRPT icon
125
Sarepta Therapeutics
SRPT
$1.64B
$8.6M 0.14%
89,219
-33,424
-27% -$3.21M
3 4
5
6 7

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q4 2023 Portfolio in Review

As of Q4 2023, Eventide Asset Management held 175 positions worth $6.13B, up 10% from $5.56B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Eventide Asset Management's Q4 2023 filing shows 20 new, 65 increased, 40 reduced and 23 closed positions. Its largest new stake was Lexeo Therapeutics: 3,002,831 shares worth $40.3M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $79.8M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 41% a quarter earlier, followed by Technology and Industrials.

  • Eventide Asset Management's largest Q4 2023 buy was Lexeo Therapeutics: 3,002,831 shares worth $40.3M.
  • Eventide Asset Management added most to Celldex Therapeutics in Q4 2023, an estimated $59.7M increase.
  • Eventide Asset Management's biggest Q4 2023 reduction was Exact Sciences, cutting an estimated $51.4M.
  • Eventide Asset Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $79.8M.
  • Eventide Asset Management's ten largest holdings make up 25% of its $6.13B portfolio in Q4 2023.
  • Eventide Asset Management opened 20 new positions and closed 23 in Q4 2023.
  • Eventide Asset Management's portfolio value rose 10% quarter-over-quarter to $6.13B.

Based on Eventide Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.